Cardiovascular comorbidity in non-alcoholic fatty liver disease

non-alcoholic fatty liver disease, cardiovascular disease, arterial hypertension, heart failure, rhythm disorders, coronary heart disease

1. Naumova L. A., Osipova O. N. Comorbidity: mechanisms of pathogenesis, clinical significance. Modern problems of science and education. 2016. No. 5, pp. 57–64.

2. I. V. Samorodskaya, E. V. Bolotova. Terminological and demographic aspects of comorbidity. Advances in Gerontology. 2016;29(3):471.

3. Drapkina O. M., Shutov A. M., Efremova E. V. Comorbidity, multimorbidity, dual diagnosis – synonyms or different concepts? Cardiovascular therapy and prevention. 2019;18(2):65–69. doi: 10.15829 / 1728–8800–2019–2–65–69.

4. Oganov R. G., Simanenkov V. I., Bakulin I. G., Bakulina N. V. et al. Comorbid pathology in clinical practice. Diagnostic and treatment algorithms. Cardiovascular therapy and prevention. 2019;18(1):5–66. doi: 10.15829/1728–8800–2019–1–5–66

5. Tirikova O. V., Kozlova N. M., Eliseev S. M., Gumerov R. R. Non-alcoholic fatty liver disease and its role in the development of cardiovascular diseases. Siberian medical journal (Irkutsk). 2015, 1, pp. 30–36.

6. Lapteva E. A., Kozlova I. V. Molecular genetic prerequisites for the comorbidity of fatty liver disease and colon pathology (review). Saratov Journal of Medical Scientific Research. 2017;13(1).:29–34.

7. Parise E. R. Nonalcoholic fatty liver disease (NAFLD), more than a liver disease NASH. Arquivos de Gastroenterologia. 2019;56(3)243–245. doi: 10.1590/s0004–2803.201900000–45

8. Akhmedov V. A. The relationship of cardiovascular complications and non-alcoholic fatty liver disease. RMZh. 2018;1 (2):86–88.

9. Lazebnik L. B., Radchenko V. G., Golovanova E. V. et al. Non-alcoholic fatty liver disease: clinical picture, diagnosis, treatment (recommendations for therapists, 2nd version). Therapy. 2017;3(13):6–23.

10. Ivashkin V. T. and others. Prevalence of non-alcoholic fatty liver disease in outpatient patients in the Russian Federation: results of the DIREG 2 study. RZHGGK-2015, 6, pp. 31–41.

11. Drapkina O. M., Korneeva O. N. The continuum of non-alcoholic fatty liver disease: from hepatic steatosis to cardiovascular risk. Rational Pharmacotherapy in Cardiology. 2016;12(4):424–429 doi: 10.20996 / 1819–6446–2016–12–4–424–429

12. Svistunov A. A., Osadchuk M. A., Kireeva N. V., Osadchuk M. M. Optimization of therapy for liver diseases not associated with viral infection. Therapeutic archive. 2018;90(2):94–99. doi: 10.26442/terarkh2018902105–111

13. Akhmedov V. A., Mamedova N. F., Gaus O. V. Non-alcoholic fatty liver disease and comorbidity. Gastroenterology of St. Petersburg. 2019;3(4):47–52.

14. Mangi M A, Rehman H, Minhas A M, et al. Non-Alcoholic Fatty Liver Disease Association with Cardiac Arrhythmias. Cureus. 2017;9(4)1–8. doi: 10.7759/cureus.1165

15. Plotnikova E. Yu. Dyslipidemia in non-alcoholic fatty liver disease as a marker of cardiovascular risk. RMZh. Medical Review. 2019;1(2):64–69.

16. Tracey G. S., Maria Esther Perez Trejo, McClelland R., Bradley R. et al. Circulating Interleukin-6 is a Biomarker for Coronary Atherosclerosis in Nonalcoholic Fatty Liver Disease: Results from the Multi-Ethnic Study of Atherosclerosis. Int J Cardiol. 2018;129(1) 77–86. doi: 10.1161/CIRCULATIONAHA.113.003625.Dyslipidemia

17. Musso G., Gambino R., Cassader M., Pagano G. Metaanalysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of noninvasive tests for liver disease severity. Annals of medicine. 2011, no.43, pp. 617–649. doi: 10.3109/07853890.2010.518623

18. Shirokova E. N. Non-alcoholic fatty liver disease, hyperlipidemia and cardiovascular risks. Consilium Medicum. 2017;19(8.2):74–76 doi: 10.26442 / 2075–1753_19.8.2.74–76

19. Tana C., Ballestri S., Ricci F., Di Vincenzo A., Ticinesi A. et al. Cardiovascular risk in non-alcoholic fatty liver disease: Mechanisms and therapeutic implications. International Journal of Environmental Research and Public Health. 2019;16(17):1–19. doi: 10.3390/ijerph16173104

20. Perera N. et al. Non-alcoholic fatty liver disease increases the mortality from acute coronary syndrome: An observational study from Sri Lanka. BMC Cardiovascular Disorders, 2016, 16, 1, стр. 4–9. doi: 10.1186/s12872–016–0212–8;

21. Sirbu O. et al. Non-alcoholic fatty liver disease-From the cardiologist perspective. Anatolian Journal of Cardiology. 2016;16(7): 534–541. doi: 10.14744/AnatolJCardiol.2016.7049

22. Liu H., Cao Y., Sun D. et al. Impact of non-alcoholic fatty liver disease on cardiovascular outcomes in patients with stable coronary artery disease: A matched case–control study. Clinical and Translational Gastroenterology. 2019, 10(2): 1–8. doi: 10.14309/ctg.0000000000000011

23. Liu Y., Zhong G., Tan H. et al. Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis. Scientific reports, 2019;9(1):1–10. doi: 10.1038/s41598–019–47687–3

24. Baharvand-Ahmadi B., Sharifi K., Namdari M. Prevalence of non-alcoholic fatty liver disease in patients with coronary artery disease. ARYA Atherosclerosis, 2016; 12(4):201–205

25. Alkagiet S., Papagiannis A., Tziomalos K. Associations between nonalcoholic fatty liver disease and ischemic stroke. World J Hepatol, 2018;10(7):474–478. doi: 10.4254/wjh.v10.i7.474

26. Ismaiel A., Colosi H., Rusu F. et al. Cardiac arrhythmias and electrocardiogram modifications inon-alcoholic fatty liver disease. A systematic review. Journal of Gastrointestinal and Liver Diseases, 2019;28(4):483–493. doi: 10.15403/jgld-344

27. Athyros V. G., Tziomalos K., Katsiki N., Doumas M. et al. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.. World Journal of Gastroenterology, 2015;21(22): 6820–6834. doi: 10.3748/wjg.v21.i22.6820

28. Lazebnik L. B., Radchenko V. G., Golovanova E. V. et al. Non-alcoholic fatty liver disease: clinical picture, diagnosis, treatment (recommendations for therapists). Therapy. 2016;2(6):6–18.

29. Fotbolcu H., Zorlu E. Nonalcoholic fatty liver disease as a multi-systemic disease. World Journal of Gastroenterology, 2016;22(16):4079–4090. doi: 10.3748/wjg.v22.i16.4079

30. Ismaiel A. et al. Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis – Literature Review. Frontiers in Medicine. 2019, 6, pp. 1–18. doi: 10.3389/fmed.2019.00202

31. Livzan M. A., Gaus O. V., Nikolaev N. A., Krolevetz T. S. NAFLD: comorbidity and associated diseases. Experimental and Clinical Gastroenterology. 2019;1(10):57–65. (In Russ.) https://doi.org/10.31146/1682–8658-ecg-170–10–57–65

32. Abenavoli L., Milic N., Di Renzo L. et al. Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2016, no.22, pp. 7006–7016. doi: 10.3748/wjg.v22.i31.7006

33. Livzan MA, Lapteva IV, Miller TS. [Role of leptin and leptin resistance in non-alcoholic fatty liver disease development in persons with obesity and overweight]. Eksp Klin Gastroenterol. 2014;(8):27–33. Russian. PMID: 25911909.

34. Heiker J. T., Kosel D., Beck-Sickinger A. G. Molecular mechanisms of signal transduction via adiponectin and adiponectin receptors. Biol Chem, 2010, no. 391, pp. 1005–1018. doi: 10.1515/BC.2010.104

35. Polyzos S. A., Aronis K. N., Kountouras J., Raptis D. D., Vasiloglou M. F., Mantzoros C. S. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia, 2016, no.59, pp. 30–43. doi: 10.1007/s00125–015–3769–3

36. Bekaert M., Verhelst X., Geerts A., Lapauw B., Calders P. Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review. Obes Rev. 2016, no.17, pp. 68–80. doi: 10.1111/obr.12333

37. Brouwers M., Simons N., Stehouwer C. et al. Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality. Diabetologia, 2020, 63, no. 2, pp. 253–260. doi: 10.1007/s00125–019–05024–3

38. Tracey G. S., Maria Esther Perez Trejo, McClelland R., Bradley R. et al. Circulating Interleukin-6 is a Biomarker for Coronary Atherosclerosis in Nonalcoholic Fatty Liver Disease: Results from the Multi-Ethnic Study of Atherosclerosis. Int J Cardiol, 2018;129(1);77–86. doi: 10.1161/CIRCULATIONAHA.113.003625.Dyslipidemia

39. Xu Y., Zhao Z., Liu S. et al. Association of Nonalcoholic Fatty Liver Disease and Coronary Artery Disease with FADS2 rs3834458 Gene Polymorphism in the Chinese Han Population. Gastroenterology Research and Practice, 2019, pp. 1–7. doi: 10.1155/2019/6069870

40. Oganov R. G., Simanenkov V. I., Bakulin I. G., et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019;18(1):5–66. (In Russ.) https://doi.org/10.15829/1728–8800–2019–1–5–66

41. Drapkina O. M., Yafarova A. A. Non-alcoholic fatty liver disease and cardiovascular risk: scientific problem state. Rational Pharmacotherapy in Cardiology. 2017;13(5):645–650. (In Russ.) https://doi.org/10.20996/1819–6446–2017–13–5–645–650

42. Zhuravlyova A. K. Non-alcoholic fatty liver disease as a predictor of cardiovascular diseases and type 2 diabetes. Experimental and Clinical Gastro entero logy. 2019;(5):144–149. (In Russ.) https://doi.org/10.31146/1682–8658-ecg-165–5–144–149

43. Zhang Y., Xu J., Wang J. et al. Changes of intestinal bacterial microbiota in coronary heart disease complicated with nonalcoholic fatty liver disease. BMC Genomics. 2019;20(1);1–12. doi: 10.1186/s12864–019–6251–7

44. Lazar V., Ditu L. M., Pircalabioru G. G., Picu A., Petcu L., Cucu N., Chifiriuc M. C. Gut Microbiota, Host Organism, and Diet Trialogue in Diabetes and Obesity. Front. Nutr. 2019;6(21):1–20. doi: 10.3389/fnut.2019.00021

45. Drapkina O. M. Liver and atherosclerosis. Gastroenterology. Effective pharmacotherapy. 2015, No. 4, pp. 14–20.

46. Sao R., Aronow W. Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis. Arch Med Sci, 2018, no.6, pp. 1233–1244. doi: 10.5114/aoms.2017.68821

47. I. G. Bakulin, M. P. Abatsiev, M. I. Skalinskaya, M. S. Zhuravleva. Clinical and medico-social significance of NAFLD through the prism of comorbidity. Therapy. 2019;6(32):76–86. doi: 10.18565

48. Aronow W. Nonalcoholic fatty liver disease is associated with coronary artery disease and subclinical atherosclerosis. Future Cardiology, 2016; 2(4): 393–396. doi: 10.2217/fca-2016–0033

49. Chandra A., Li W., Stone C. et al. The cerebral circulation and cerebrovascular disease I: Anatomy. Brain circulation. Brain Circulation, 2017;3(1):35–40. doi: 10.4103/bc.bc

50. Dinani A., Sanyal A. Nonalcoholic fatty liver disease: Implications for cardiovascular risk. Cardiovascular Endocrinolog y, 2017;6(2);62–72. doi: 10.1097/XCE.0000000000000126

51. Nazarova M. B. Arterial hypertension and non-alcoholic fatty liver disease. Fundamental and applied scientific research. 2019, pp. 173–174.

52. Li H, Hu B, Wei L, Zhou L, Zhang L, Lin Y, Qin B, Dai Y, Lu Z. Non-alcoholic fatty liver disease is associated with stroke severity and progression of brainstem infarctions. Eur J Neurol. 2018, no. 25, pp. 577. doi: 10.1111/ene.13556

53. Käräjämäki A. J., Pätsi O. P., Savolainen M., Kesäniemi Y. A., Huikuri H., Ukkola O. Non- Alcoholic Fatty Liver Disease as a Predictor of Atrial Fibrillation in Middle-Aged Population (OPERA Study). PLoS ONE, 2015;10(11):1–13. doi:10.1371/journal.pone.0142937

54. Fargion S., Porzio M., Fracanzani A. Nonalcoholic fatty liver disease and vascular disease: State-of-the-art. World Journal of Gastroenterology, 2014;20(37): 13306–13324 doi: 10.3748/wjg.v20.i37.13306

55. Serov I. S., Blokhina I. I., Shagina V. N. Non-alcoholic fatty liver disease as a risk factor for cardiovascular diseases. Young scientist. 2019;37(275): 112–114.

56. Wójcik-Cichy K., Koślińska-Berkan K., Piekarska A. The influence of NAFLD on the risk of atherosclerosis and cardiovascular diseases. Clin Exp HEPATOL. 2018;4(1);1–6. doi: 10.5114/ceh.2018.73155

57. Khovasova N. O., Vertkin A. L. Vascular comorbidity – a new trend in the outpatient department. Therapy. 2015;1(1):38–44.

58. Golabi P., Fukui N., Paik J., Sayiner M., Mishra A., Younossi Z. Mortality Risk Detected by Atherosclerotic Cardiovascular Disease Score in Patients With Nonalcoholic Fatty Liver Disease. Hepatology Communications, 2019;3(8):1050–1060. doi: 10.1002/hep4.1387

59. Zhang Z., Wang P., Guo F. et al. Chronic heart failure in patients with nonalcoholic fatty liver disease: prevalence, clinical features and relevance. Journal of International Medical Research. 2018;46(9):3959–3969. doi: 10.1177/0300060518782780

60. Bellentani S., Dalle G. R., Suppini A., Marchesini G. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology. 2008, no.47, pp. 746–754. doi: 10.1002/hep.22009

61. Eganyan R. A. The role of non-alcoholic fatty liver disease in the development of cardiovascular diseases. CardioSomatics. 2018;9(1):47–53.